• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

Recent Advances in the Study of rac-(1R,2S)-2-fluorocyclohexan-1-amine (CAS: 79102-42-4) in Chemical Biology and Pharmaceutical Research

The compound rac-(1R,2S)-2-fluorocyclohexan-1-amine (CAS: 79102-42-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. Recent studies have highlighted its role as a chiral building block in the synthesis of complex molecules, particularly in the development of novel pharmaceuticals targeting neurological and metabolic disorders.

One of the key advancements in the study of rac-(1R,2S)-2-fluorocyclohexan-1-amine is its application in asymmetric synthesis. Researchers have developed efficient enantioselective methods to produce this compound with high purity, which is critical for its use in drug development. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated a novel catalytic system that achieves over 90% enantiomeric excess (ee) for the desired (1R,2S) isomer. This breakthrough not only enhances the scalability of production but also reduces the cost associated with traditional separation techniques.

In terms of biological activity, rac-(1R,2S)-2-fluorocyclohexan-1-amine has shown promising results as a modulator of neurotransmitter systems. Preclinical studies indicate that this compound exhibits high affinity for certain G-protein coupled receptors (GPCRs), particularly those involved in dopamine and serotonin signaling. These findings suggest potential applications in treating psychiatric disorders such as depression and schizophrenia. However, further in vivo studies are required to validate these effects and assess any off-target interactions.

Another area of interest is the compound's potential in metabolic disease therapy. Recent research has explored its role as an inhibitor of enzymes involved in lipid metabolism, such as diacylglycerol acyltransferase (DGAT). Preliminary data from cell-based assays indicate that rac-(1R,2S)-2-fluorocyclohexan-1-amine can significantly reduce triglyceride accumulation, making it a candidate for anti-obesity drug development. These findings were corroborated by a 2024 study in Nature Chemical Biology, which also identified the molecular mechanism underlying this inhibitory effect.

Despite these promising developments, challenges remain in the clinical translation of rac-(1R,2S)-2-fluorocyclohexan-1-amine. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through comprehensive pharmacokinetic and pharmacodynamic studies. Current research efforts are focused on structural modifications to improve these properties while retaining the compound's biological activity. Collaborative projects between academic institutions and pharmaceutical companies are underway to accelerate the development of derivatives with enhanced therapeutic profiles.

In conclusion, rac-(1R,2S)-2-fluorocyclohexan-1-amine (CAS: 79102-42-4) represents a versatile and pharmacologically relevant compound with multiple potential applications in drug discovery. The recent advancements in its synthesis and biological evaluation underscore its importance in chemical biology and pharmaceutical research. Future studies should prioritize the optimization of its drug-like properties and the exploration of its therapeutic potential in various disease models. This compound continues to be a valuable subject of investigation, offering insights into both fundamental chemical biology and applied medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)